Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination

International Journal of Medical Microbiology

Volumn 294, Issue 1, 2004, Pages 35-44

  Hahn, Ulrike K ^a   Alex, Michaela ^b   Czerny, Claus Peter ^b   Böhm, Reinhard ^a   Beyer, Wolfgang ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bacillus anthracis; DNA vaccination; Mice; STI spores

Indexed keywords

BACILLUS ANTHRACIS ANTIGEN; BACTERIAL ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; PLASMID VECTOR; PROTEIN PA63; PROTEIN PA83; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOPLASMIC RETICULUM; EUKARYOTE; EXPRESSION VECTOR; GENE GUN; GENE TARGETING; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INOCULATION; LETHAL MUTANT; MOUSE; NONHUMAN; SPLEEN CELL; STATISTICAL SIGNIFICANCE; VACCINATION;

BACILLUS ANTHRACIS;

EID: 3142758518     PISSN: 14384221     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmm.2003.12.002     Document Type: Article

References (29)

1. Beedham, R.J., Turnbull, P.C.B., Williamson, E.D., 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19, 4409-4416.
2. Boyle, J.S., Koniaras, C., Lew, A.M., 1997. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int. Immunol. 9, 1897-1906.
3. Brossier, F., Levy, M., Mock, M., 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70, 661-664.
4. Bucht, G., Sjolander, K.B., Eriksson, S., Lindgren, L., Lundkvist, A., Elgh, F., 2001. Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. Vaccine 19, 3820-3829.
5. Duesbery, N.S., Webb, C.P., Leppla, S.H., Gordon, V.M., Klimpel, K.R., Copeland, T.D., Ahn, N.G., Oskarsson, M.K., Fukasawa, K., Vande Woude, G.F., 1998. Proteolytic inactivation of MAP-kinase by anthrax lethal factor. Science 280, 734-737.
6. Feltquate, D.M., Heaney, S., Webster, R.G., Robinson, H.L., 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158, 2278-2284.
7. Flick-Smith, H.C., Walker, N.J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., Titball, R.W., Williamson, E.D., 2002. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70, 1653-1656.
8. Fowler, K., McBride, B.W., Turnbull, P.C., Baillie, L.W., 1999. Immune correlates of protection against anthrax. J. Appl. Microbiol. 87, 305.
9. Gu, M.-L., Leppla, S.H., Klinman, D.M., 1999. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17, 340-344.
10. Hansen, M.B., Nielsen, S.E., Berg, K., 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203-210.
11. Ivins, B.E., Welkos, S.L., 1988. Recent advances in the development of an improved human anthrax vaccine. Eur. J. Epidemiol. 4, 12-19.
12. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58, 303-308.
13. Ivins, B.E., Welkos, S.L., Little, S.F., Crumrine, M.H., Nelson, G.O., 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60, 662-668.
14. Leppla, S.H., 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic amp concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79, 3162-3166.
15. Leppla, S.H., 1995. Anthrax toxins. In: Moss, J., Iglewski, B., Vaughan, M., Tu, A. (Eds.), Toxins and Virulence Factors in Disease - Bacterial Handbook of Natural Toxins. Marcel Dekker Inc, New York, NY, pp. 543-572.
16. Pellizzari, R., Guidi-Rontani, C., Vitale, G., Mock, M., Montecucco, C., 2000. Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages. Int. J. Med. Microbiol. 290, 421-427.
17. Pitt, M.L.M., Ivins, B.E., Estep, J.E., Farchaus, J., Friedlander, A.M., 1996. Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax. Salisbury Med. Bull. 87, 130.
18. Pitt, M.L., Little, S.F., Ivins, B.E., Fellows, P., Barth, J., Hewetson, J., Gibbs, P., Dertzbaugh, M., Friedlander, A.M., 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 (32), 4768-4773.
19. Price, B.M., Liner, A.L., Park, S., Leppla, S.H., Mateczun, A., Galloway, D.R., 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69, 4509-4515.
20. Reuveny, S., White, M.D., Adar, Y.Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D., Shafferman, A., Velan, B., 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69, 2888-2893.
21. Riemenschneider, J., Garrison, A., Geisbert, J., Jahrling, P., Hevey, M., Negley, D., Schmaljohn, A., Lee, J., Hart, M.K., Vanderzanden, L., Custer, D., Bray, M., Ruff, A., Ivins, B., Bassett, A., Rossi, C., Schmaljohn, C., 2003. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21, 4071-4080.
22. Scheiblhofer, S., Chen, D., Weiss, R., Khan, F., Mostboeck, S., Fegeding, K., Leitner, W.W., Thalhamer, J., Lyon, J.A., 2001. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequences from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection. Eur. J. Immunol. 31, 692-698.
23. Thalhamer, J., Leitner, W., Hammerl, P., Brtko, J., 2001. Designing immune responses with genetic immunization and immunostimulatory DNA sequences. Endocr. Regul. 35, 143-166.
24. Turnbull, P.C.B., Quinn, C.P., Hewson, R., Stockbridge, M.C., Melling, J., 1990. Protection conferred by microbially supplemented UK and purified PA vaccines. Proc. Int. Workshop Anthrax Salisbury Med. Bull. 68 (Special Suppl.), 89-91.
25. Welkos, S.L., Keener, T.J., Gibbs, P.H., 1986. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51, 795-800.
26. Welkos, S.L., Becker, D., Friedlander, A.M., Trotter, R., 1990. Pathogenesis and host resistance to Bacillus anthracis: a mouse model. Salisbury Med. Bull. 68 (Special Suppl.), 49-52.
27. Welkos, S.L., Vietri, N.J., Gibbs, P.H., 1993. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pXO2 and chromosome in strain-dependent virulence. Microb. Pathog. 14, 381-388.
28. Welkos, S., Little, S., Friedlander, A., Fritz, D., Fellows, P., 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147, 1677-1685.
29. Williamson, E.D., Beedham, R.J., Bennett, A.M., Perkins, S.D., Miller, J., Baillie, L.W.J., 1999. Presentation of protective antigen to the mouse immune system: immune sequelae. J. Appl. Microbiol. 87, 315-317.